Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-31
2005-05-31
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S023000, C514S042000, C514S045000, C514S046000, C514S035000, C536S004100, C536S018700, C536S017200, C536S109000
Reexamination Certificate
active
06900182
ABSTRACT:
Compositions comprising inositolphosphoglycans (IPGs) and ribose are disclosed, and their use in the prevention or treatment of ischaemic-reperfusion injury. This treatment increases the energy generating systems of cells by employing the mitochondrial oxidative restoration system. The use of the compositions in preserving organs for transplantation is also disclosed.
REFERENCES:
patent: 4880783 (1989-11-01), Mentzer et al.
patent: WO 9811435 (1998-03-01), None
Pliml et al.(Clinical investigator, (Oct. 1993) 71 (10) 770-3) (Abstract sent).*
Asplin et al.,P.N.A.S.90:5924-5928, 1993.
Berne,Amer. J. Physio., 204:317-322, 1963.
Bouchard and Lamontagne,Cardiovasc. Res., 37:82-90, 1998.
Bromme and Holz,Mol. Cell Biochem. 163-164:261-275, 1996.
Bozkurt et al.,Cardiovasc. Surg., 5; 117-124, 1997.
Caro et al.,Biochem. Molec. Med., 61:214-228, 1997.
Choong and Gavin,J. Cardiovasc. Surg. (Torino), 37:275-284, 1996.
de Jong et al.,Eur. J. Pharmacol., 337:41-44, 1997.
Ferrari et al.,Cardiovasc. Drugs Ther., 10:425-437, 1996.
Gilad et al., .Mol. Cell Cardiol., 29:2585-2597, 1997.
Hillier et al.,Amer. J. Epidemiol., 128:402-409, 1988.
Houston et al.,J. Cell Mol. Cardiol., 29:1763-1766, 1997.
Jaramillo et al.,J. Org. Chem., 59:3135-3141, 1994.
Konorev et al.,Br. J. Pharmacol., 199:511-518, 1986.
Kunjara et al.,Biochem J., 244:101-108, 1987.
Loh et al.,Br. J. Pharmacol., 118:1905-1012, 1996.
Mangano,J. Amer. Med. Assoc., 277:325-332, 1997.
Meldrum et al.,Immunology92:472-477, 1997.
Muhlhauser et al.,Diabetologia, 40:1492-1493, 1997.
Pernow & Wang,Cardiovasc. Res., 33:518-526, 1997.
Rademacher et al.,Brazilian J. Med. Biol. Res., 27:327-341, 1994.
Russ et al.,Pflügers Arch., 433:26-34, 1996.
Smits & Their,Diabetologia38:116-212, 1995.
Stanley et al.,Cardiovasc. Res., 33:243-257, 1997.
Thiemermann et al.,P.N.A.S. (USA), 94:679-683, 1997.
Varela-Nieto et al.,Comp. Biochem. Physiol., 115:223-241, 1998.
Zapata et al.,Carbohydrate Res., 264:21-31, 1994.
Zimmer,J. Physiol.(Paris), 76:769-775, 1980.
Zimmer,Science, 220:81-82, 1983.
Zimmer,Mol. Cell Biochem., 160-161, 101-109, 1996.
Zingarelli et al.,Shock, 5:258-264, 1996.
Zubairu et al.,J. Neurochemistry, 41:76-83, 1983.
Danforth et al.,Circ. Res., 7:965-870, 1983.
Goodwin et al.,Eur. J. Cardiothorac. Surg., 11:981-987.
Kunjara et al., In:Biopolymers and BioproductsStructure , Function and Applications, Ed. Svati et al., 301-305, 1995.
Greenbaum Leslie
McLean Patricia
Rademacher Thomas William
Henry Michael C.
Quine Jonathan Alan
Quine Intellectual Property Law Group P.C.
Sylus Pharmaceuticals Ltd.
Wilson James O.
LandOfFree
Inositolphosphoglycan and ribose for treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inositolphosphoglycan and ribose for treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inositolphosphoglycan and ribose for treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3384402